Table 3.
Characteristics, efficacy, and safety data of bispecific antibodies in RRMM.
| Agents | Type | Phase | Target | Number of Patients | ORR (%) | CRS (%) | NCT Number | References |
|---|---|---|---|---|---|---|---|---|
| AMG420 | BiTE | 1 | BCMAxCD3 | 42 | 70 | 38 | NCT03836053 | [94] |
| AMG701 | BiTE | 1/2 | BCMAxCD3 | 75 | 83 | 61 | NCT03287908 | [95] |
| Teclistamab (JNJ-64007957) | BsAb | 1/2 | BCMAxCD3 | 149 | 69 | 55 |
NCT04557098 NCT03145181 |
[96,97,98] |
| REGN5458 | BsAb | 1/2 | BCMAxCD3 | 49 | 62.5 | 39 | NCT03761108 | [99] |
| TNB-383B | BsAb | 1 | BCMAxCD3 | 58 | 80 | 45 | NCT03933735 | [100] |
| Elranatamab (PF-06863135) | BsAb | 2 | BCMAxCD3 | 30 | 83.3 | 73 | NCT04649359 | [101] |
| CC-93269 | BsAb | 1 | BCMAxCD3 | 30 | 89 | 77 | NCT03486067 | [102] |
| GBR1342 | BiTE | 1 | CD38xCD3 | 19 | NR | NR | NCT03309111 | [103] |
| AMG424 | BsAb | 1 | CD38xCD3 | NR | NR | NR | NCT03445663 | [104] |
| Talquetamab (JNJ-64407564) | BsAbs | 1 | GPRC5dxCD3 | NR | NR | NR |
NCT04108195 NCT03399799 NCT04773522 |
[105,106] |
| Cevostamab (BFCR4350A) | BiTE | 1 | FCRH5xCD3 | 160 | 54.8% | 80.7% | NCT03275103 | [107] |
ORR = overall response rate and CRS = cytokine release syndrome.